Teva Pharmaceutical Industries announces plans to transform into a leading biopharmaceutical company, targeting $5 billion in innovative medicines by 2030.
Quiver AI Summary
Teva Pharmaceutical Industries Ltd. announced an acceleration phase of its “Pivot to Growth” strategy aimed at transforming the company into a leading global biopharmaceutical player. During its 2025 Innovation & Strategy Day, Teva shared plans to build an innovative medicines franchise projected to exceed $5 billion by 2030, driven by key products like AUSTEDO®, AJOVY®, and UZEDY®. The company reaffirmed its financial targets for 2027, including a 30% operating profit margin, and highlighted significant revenue growth from its innovative portfolio and a robust pipeline of late-stage assets. Teva's generics and biosimilars business remains strong, with plans for continued expansion and a focus on complex generics. Overall, Teva aims to enhance shareholder value through innovation and operational efficiency while addressing the evolving needs of patients worldwide.
Potential Positives
- Teva is projected to exceed $5 billion in its innovative medicines franchise by 2030, indicating strong growth potential in its portfolio.
- The company has achieved nine consecutive quarters of growth, showcasing a successful turnaround strategy and a solid foundation for future expansion.
- Teva reaffirmed ambitious 2027 financial targets, including a 30% operating profit margin, signaling confidence in its growth strategy and operational improvements.
- Multiple late-stage pipeline assets with significant peak sales potential have been identified, enhancing Teva's position in the biopharma industry with promising future products.
Potential Negatives
- Teva's significant dependence on its generic products may limit its growth potential as it faces increasing competition in the marketplace.
- The press release emphasizes uncertainty regarding the achievement of peak sales targets and operational goals, reflecting potential vulnerabilities in their strategic execution.
- Operational risks arising from geopolitical conflicts, particularly the ongoing situation in Israel, could adversely impact Teva's facilities and overall business operations.
FAQ
What is Teva's growth strategy outlined in the press release?
Teva is accelerating its "Pivot to Growth" strategy to become a leading biopharmaceutical company with a focus on innovative medicines.
Which products are driving Teva's innovative medicines franchise?
AUSTEDO®, AJOVY®, and UZEDY® are key products expected to contribute to Teva’s innovative medicines franchise exceeding $5 billion by 2030.
What are Teva's 2027 financial targets?
Teva aims to achieve a 30% operating profit margin and over $2.7 billion in free cash flow by 2027.
How does Teva plan to support its generics business?
Teva will focus on complex generics and biosimilars, with plans for five new product launches by 2027 to maintain market leadership.
What are Teva's late-stage pipeline assets?
Teva's late-stage pipeline includes duvakitug and DARI, which have significant sales potential to enhance its innovative portfolio.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TEVA Insider Trading Activity
$TEVA insiders have traded $TEVA stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- ROBERTO MIGNONE sold 286,000 shares for an estimated $6,294,030
- MARK SABAG (See "Remarks") sold 337,915 shares for an estimated $6,097,304
- RICHARD DANIELL (Exec. VP, European Commercial) has made 0 purchases and 10 sales selling 273,583 shares for an estimated $4,345,473.
- ERIC A HUGHES (See "Remarks") has made 0 purchases and 4 sales selling 48,151 shares for an estimated $767,057.
- RICHARD D FRANCIS (President and CEO) has made 0 purchases and 2 sales selling 23,773 shares for an estimated $375,533.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TEVA Hedge Fund Activity
We have seen 258 institutional investors add shares of $TEVA stock to their portfolio, and 302 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. added 22,044,407 shares (+197885.2%) to their portfolio in Q1 2025, for an estimated $338,822,535
- RUBRIC CAPITAL MANAGEMENT LP added 8,550,000 shares (+50.3%) to their portfolio in Q1 2025, for an estimated $131,413,500
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 6,990,407 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $107,442,555
- GOLDMAN SACHS GROUP INC added 6,859,718 shares (+195.1%) to their portfolio in Q1 2025, for an estimated $105,433,865
- GLENVIEW CAPITAL MANAGEMENT, LLC added 6,322,317 shares (+74.8%) to their portfolio in Q1 2025, for an estimated $97,174,012
- PHOENIX FINANCIAL LTD. added 6,252,030 shares (+29.5%) to their portfolio in Q1 2025, for an estimated $96,093,701
- DUQUESNE FAMILY OFFICE LLC added 5,882,350 shares (+65.4%) to their portfolio in Q1 2025, for an estimated $90,411,719
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TEVA Analyst Ratings
Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 12/18/2024
- Barclays issued a "Overweight" rating on 12/18/2024
- Bank of America Securities issued a "Buy" rating on 12/03/2024
To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.
$TEVA Price Targets
Multiple analysts have issued price targets for $TEVA recently. We have seen 2 analysts offer price targets for $TEVA in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $28.0 on 12/18/2024
- Balaji Prasad from Barclays set a target price of $28.0 on 12/18/2024
Full Release
Teva outlines acceleration path into a leading biopharma company
Innovative medicines franchise on track to exceed $5 billion by 2030, led by
AUSTEDO
®
(deutetrabenazine), AJOVY
®
(fremanezumab), UZEDY
®
(risperidone) and
late-stage pipeline with blockbuster potential
Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs
TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond.
Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at:
https://ir.tevapharm.com/Events-and-Presentations
.
Where We Are Today
Teva has completed Phase 1 of the Strategy: Return to Growth, delivering:
9 consecutive quarters of growth – fueled by strong momentum from key innovative growth drivers.
More than $2.3 billion in revenue in 2024 from Teva’s innovative portfolio: AUSTEDO
®
, AJOVY
®
, and UZEDY
®
.
Returning the generics business to growth with +5% in revenues across regions, and top 3 global portfolio with potential for five product launches by 2027.
“The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company – more focused, more innovative, and more robust. I am proud that we have delivered on our commitments,” said Richard Francis, Teva’s President and CEO. “Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio.”
Delivering on Our Growth Engines
Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a >$5 billion innovative medicines franchise by 2030, driven by AUSTEDO, AJOVY, UZEDY, and a robust pipeline of late-stage assets including olanzapine LAI, duvakitug, DARI, and emrusolmin.
AUSTEDO
: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030.
AJOVY
: A globally established brand with presence across 43 countries and expected launches in 3 additional countries this year.
LAI schizophrenia franchise expected to have $1.5 billion to $2.0 billion in peak sales
UZEDY
: Fastest growing LAI with >60% risperidone LAI market share captured.
Olanzapine LAI
: Set to expand our LAI franchise - U.S. NDA filing expected in H2 2025.
Stepping Up Innovation
Teva’s late-stage pipeline includes multiple assets with proven mechanisms and blockbuster potential:
duvakitug (anti-TL1A):
A potentially best-in-class treatment for inflammatory bowel disease, with potential expansion into additional indications with peak sales potential of up to $2-$5 billion.
DARI:
A dual-action rescue inhaler for asthma, that could address a significant unmet need as a first ICS/SABA combination for both adult and pediatric patient populations, with peak sales potential of ~$1 billion.
olanzapine LAI:
A differentiated long-acting injectable for schizophrenia, that we expect to build on the success of UZEDY and expand Teva’s LAI franchise.
emrusolmin:
A potential first-in-class treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease that currently has no approved treatments, with peak sales potential of more than $2 billion.
TEV-‘408
: Anti-IL-15 antibody granted fast-track designation by the U.S. Food and Drug Administration (FDA) to be evaluated for the treatment of celiac disease, with peak sales potential of more than $1 billion.
Sustaining Our Generics Powerhouse
Teva’s generics, biosimilars, and OTC business remains a stable, robust and cash-generating powerhouse. Teva continues to lead in generics globally, with a strong pipeline of complex generics and biosimilars.
13 biosimilars in the pipeline, with potential for 5 new launches planned by 2027.
Strategic focus on complex generics, biosimilars, and OTC to compensate gRevlimid by 2027.
Expanding on our $1.1 billion OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth.
Continued manufacturing transformation to enhance competitiveness and margins.
Focusing Our Business
Teva is accelerating shareholder value creation with reaffirmed its 2027 financial targets:
Revenue growth driven by innovative launches and stable generics business.
Operating margin expansion to 30% by 2027.
Free cash flow of >$2.7 billion in 2027 and >$3.5 billion by 2030.
Payment of debt down to 2x net leverage.
~$700 million in net savings through modernizing the organization and improving operational efficiencies, enabling reinvestment in R&D and commercial capabilities.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit
www.tevapharm.com
.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. Important factors that could cause or contribute to such differences include risks relating to:
our ability to successfully compete in the marketplace, including: uncertainty of achieving financial and operational targets, including peak sales, or the timing for achievement of such targets; that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in additional costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.;
our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business;
compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; the effects of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan
®
(naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement (“DPA”) with the U.S. Department of Justice (“DOJ”); potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare, Medicaid and other governmental programs reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of ESG issues;
the impact of the state of war declared in Israel and the military activity in the region, including the risk of disruptions to our operations and facilities, such as our manufacturing and R&D facilities, located in Israel, the impact of our employees who are military reservists being called to active military duty, and the impact of the war on the economic, social and political stability of Israel;
other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate, and the effects of such developments on sales of our products and the pricing and availability of our raw materials; and the impact of any future failure to establish and maintain effective internal control over our financial reporting;
and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
